Arena Pharmaceuticals (ARNA) Receives Daily Media Impact Rating of 0.09
News articles about Arena Pharmaceuticals (NASDAQ:ARNA) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.2006295343381 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of research firms have issued reports on ARNA. BidaskClub downgraded Arena Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, June 23rd. ValuEngine raised Arena Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 1st. Credit Suisse Group lowered their price target on Arena Pharmaceuticals from $58.00 to $56.00 and set an “outperform” rating for the company in a research report on Tuesday, August 7th. Finally, Royal Bank of Canada began coverage on Arena Pharmaceuticals in a research report on Thursday, May 31st. They set an “outperform” rating and a $65.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $60.38.
Shares of NASDAQ ARNA traded up $1.36 on Friday, hitting $42.18. The company had a trading volume of 518,985 shares, compared to its average volume of 429,246. Arena Pharmaceuticals has a 12-month low of $24.07 and a 12-month high of $50.05. The company has a quick ratio of 28.76, a current ratio of 28.76 and a debt-to-equity ratio of 0.10.
In other news, EVP Steven W. Spector sold 29,005 shares of the company’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $36.01, for a total value of $1,044,470.05. Following the completion of the sale, the executive vice president now owns 48,695 shares of the company’s stock, valued at $1,753,506.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.92% of the stock is owned by corporate insiders.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease.
Featured Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.